TIA1 and cancer: Analyses of clinical samples from PC patients with a high-grade (Gleason 8-10) and locally advanced disease (pT3N0M0), revealed that those with IL-30−/−PC, devoid of IL-30 in both cancer and immune cells, showed distinct TIA-1+ CD4+ CTLs, rare Tregs, and a lower biochemical recurrence rate, compared to patients with IL-30+/+PC, showing IL-30 expression in both cancer and infiltrating immune cells [91].